Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large-cell lymphoma treated with brentuximab vedotin: A case series

被引：1
|
作者：
Contarini, Giorgia [1 ,2 ]
Carraro, Elisa [1 ]
Lovisa, Federica [2 ]
Martire, Gaia [1 ,2 ]
Lo Nigro, Luca [3 ]
Sala, Alessandra [4 ]
Pillon, Marta [1 ]
Mussolin, Lara [1 ,2 ]
机构：
[1] Univ Padua, Oncol & Stem Cell Transplant Ctr, Maternal & Child Hlth Dept Pediat Hematol, Padua, Italy
[2] Pediat Res Inst Citta Speranza, Padua, Italy
[3] Azienda Policlin San Marco, Ctr Pediat Hematol Oncol, Catania, Italy
[4] Univ Milano Bicocca, Fdn IRCCS San Gerardo Tintori, Ctr Maria Letizia Verga, Dept Pediat Hematol Oncol, Monza, Italy
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 204卷 / 01期
关键词：
CHILDREN;
D O I：
10.1111/bjh.19151
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：352 / 355
页数：4
相关论文
共 50 条
  • [21] The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma
    Chihara, Dai
    Fanale, Michelle A.
    Noorani, Mansoor
    Westin, Jason R.
    Nastoupil, Loretta
    Hagemeister, Fredrick B.
    Fayad, Luis E.
    Romaguera, Jorge E.
    Samaniego, Felipe
    Turturro, Francesco
    Lee, Hun Ju
    Neelapu, Sattva S.
    Rodriguez, Alma
    Wang, Michael
    Fowler, Nathan
    Miranda, Roberto N.
    Hosing, Chitra M.
    Nieto, Yago
    Davis, Richard Eric
    Oki, Yasuhiro
    BLOOD, 2015, 126 (23)
  • [22] Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
    Shustov, Andrei R.
    Advani, Ranjana
    Brice, Pauline
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Illidge, Tim
    Matous, Jeffrey
    Ramachandren, Radhakrishnan
    Fanale, Michelle A.
    Connors, Joseph M.
    Yang, Yin
    Sievers, Eric L.
    Kennedy, Dana A.
    Pro, Barbara
    BLOOD, 2010, 116 (21) : 423 - 424
  • [23] REAL LIFE EXPERIENCE WITH BRENTUXIMAB VEDOTIN: THE ITALIAN STUDY ON 40 RELAPSED/REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA PATIENTS
    Quirini, F.
    Broccoli, A.
    Pellegrini, C.
    Di Rocco, A.
    Puccini, B.
    Patti, C.
    Gini, G.
    Mannina, D.
    Tani, M.
    Rusconi, C.
    Romano, A.
    Vanazzi, A.
    Botto, B.
    Carlo-Stella, C.
    Hoaus, S.
    Musto, P.
    Mazza, P.
    Molica, S.
    Corradini, P.
    Fama, A.
    Gaudio, F.
    Merli, M.
    Gravetti, A.
    Gritti, G.
    Arcari, A.
    Tosi, P.
    Liberati, A. M.
    Pinto, A.
    Pavone, V.
    Gherlinzoni, F.
    Naso, V.
    Volpetti, S.
    Trentin, L.
    Goldaniga, M. C.
    Bonfichi, M.
    De Renzo, A.
    Schiavotto, C.
    Spina, M.
    Storti, S.
    Carella, A. M.
    Stefoni, V.
    Argnani, L.
    Zinzani, P. L.
    HAEMATOLOGICA, 2017, 102 : 50 - 51
  • [24] Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma
    Ogura, Michinori
    Tobinai, Kensei
    Hatake, Kiyohiko
    Ishizawa, Kenichi
    Uike, Naokuni
    Uchida, Toshiki
    Suzuki, Tatsuya
    Aoki, Tomohiro
    Watanabe, Takashi
    Maruyama, Dai
    Yokoyama, Masahiro
    Takubo, Takatoshi
    Kagehara, Hideaki
    Matsushima, Takafumi
    CANCER SCIENCE, 2014, 105 (07) : 840 - 846
  • [25] Brentuximab Vedotin and High-dose Methotrexate Administrated Alternately for Refractory Anaplastic Large-cell Lymphoma With Central Nervous System Disease
    Mitsunobu, Takuro
    Nishikawa, Takuro
    Kusuda, Masaki
    Nakagawa, Shunsuke
    Kodama, Yuichi
    Okamoto, Yasuhiro
    Kawano, Yoshifumi
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2020, 42 (06) : E456 - E458
  • [26] PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA OR SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA: INTERIM PHASE 1 SAFETY AND PHARMACOKINETIC DATA
    Locatelli, F.
    Gore, L.
    Mauz-Koerholz, C.
    Rosolen, A.
    Landman-Parker, J.
    de Toledo, J.
    Beishuizen, A.
    Fasanmade, A.
    Wang, J.
    Fingert, H.
    Labotka, R.
    Neville, K.
    HAEMATOLOGICA, 2013, 98 : 68 - 68
  • [27] Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma
    Zinzani, Pier Luigi
    Gandolfi, Letizia
    Casadei, Beatrice
    Pellegrini, Cinzia
    Broccoli, Alessandro
    Derenzini, Enrico
    Quirini, Federica
    Tonialini, Lorenzo
    Cavo, Michele
    Argnani, Lisa
    Stefoni, Vittorio
    BLOOD, 2015, 126 (23)
  • [28] LONG-TERM RESPONDERS AFTER BRENTUXIMAB VEDOTIN: EXPERIENCE ON 57 PATIENTS WITH RELAPSED AND REFRACTORY HODGKIN AND ANAPLASTIC LARGE CELL LYMPHOMA
    Gandolfi, L.
    Celli, M.
    Pellegrini, C.
    Casadei, B.
    Morigi, A.
    Stefoni, V.
    Broccoli, A.
    Quirini, F.
    Tonialini, L.
    Argnani, L.
    Cavo, M.
    Zinzani, P. L.
    HAEMATOLOGICA, 2015, 100 : 3 - 3
  • [29] Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update
    Advani, Ranjana H.
    Shustov, Andrei R.
    Brice, Pauline
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Illidge, Tim
    Matous, Jeffrey
    Ramchandren, Radhakrishnan
    Fanale, Michelle A.
    Connors, Joseph M.
    Yang, Yin
    Kennedy, Dana A.
    Pro, Barbara
    BLOOD, 2011, 118 (21) : 204 - 204
  • [30] Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma
    Advani, Ranjana
    Pro, Barbara
    Kennedy, Dana
    Fanale, Michelle
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB4 - AB4
12345